IN2013MN02441A - - Google Patents

Download PDF

Info

Publication number
IN2013MN02441A
IN2013MN02441A IN2441MUN2013A IN2013MN02441A IN 2013MN02441 A IN2013MN02441 A IN 2013MN02441A IN 2441MUN2013 A IN2441MUN2013 A IN 2441MUN2013A IN 2013MN02441 A IN2013MN02441 A IN 2013MN02441A
Authority
IN
India
Prior art keywords
polypeptide
derived
amino acid
molecules
acid sequence
Prior art date
Application number
Other languages
English (en)
Inventor
Brendan P Eckelman
John C Timmer
Peter L Nguy
Grant B Guenther
Quinn Deveraux
Original Assignee
Inhibrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Llc filed Critical Inhibrx Llc
Publication of IN2013MN02441A publication Critical patent/IN2013MN02441A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
IN2441MUN2013 2011-06-28 2012-06-28 IN2013MN02441A (enrdf_load_stackoverflow)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502055P 2011-06-28 2011-06-28
US201161570394P 2011-12-14 2011-12-14
US201161577204P 2011-12-19 2011-12-19
US201261638168P 2012-04-25 2012-04-25
PCT/US2012/044730 WO2013003641A2 (en) 2011-06-28 2012-06-28 Serpin fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2013MN02441A true IN2013MN02441A (enrdf_load_stackoverflow) 2015-06-12

Family

ID=47424806

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2441MUN2013 IN2013MN02441A (enrdf_load_stackoverflow) 2011-06-28 2012-06-28

Country Status (28)

Country Link
US (8) US8980266B2 (enrdf_load_stackoverflow)
EP (2) EP2726092B1 (enrdf_load_stackoverflow)
JP (5) JP2014523900A (enrdf_load_stackoverflow)
KR (6) KR102756547B1 (enrdf_load_stackoverflow)
CN (3) CN103917563A (enrdf_load_stackoverflow)
AU (4) AU2012275287B2 (enrdf_load_stackoverflow)
BR (1) BR112013033799A2 (enrdf_load_stackoverflow)
CA (2) CA2839619C (enrdf_load_stackoverflow)
CY (1) CY1122195T1 (enrdf_load_stackoverflow)
DK (1) DK2726092T3 (enrdf_load_stackoverflow)
ES (1) ES2746052T3 (enrdf_load_stackoverflow)
HR (1) HRP20191652T1 (enrdf_load_stackoverflow)
HU (1) HUE046156T2 (enrdf_load_stackoverflow)
IL (3) IL312872A (enrdf_load_stackoverflow)
IN (1) IN2013MN02441A (enrdf_load_stackoverflow)
LT (1) LT2726092T (enrdf_load_stackoverflow)
ME (1) ME03473B (enrdf_load_stackoverflow)
MX (2) MX356517B (enrdf_load_stackoverflow)
NZ (1) NZ744257A (enrdf_load_stackoverflow)
PL (1) PL2726092T3 (enrdf_load_stackoverflow)
PT (1) PT2726092T (enrdf_load_stackoverflow)
RS (1) RS59368B1 (enrdf_load_stackoverflow)
RU (4) RU2727452C1 (enrdf_load_stackoverflow)
SG (2) SG10201601621PA (enrdf_load_stackoverflow)
SI (1) SI2726092T1 (enrdf_load_stackoverflow)
SM (1) SMT201900520T1 (enrdf_load_stackoverflow)
UA (1) UA124083C2 (enrdf_load_stackoverflow)
WO (1) WO2013003641A2 (enrdf_load_stackoverflow)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178102A2 (en) * 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying serpin containing fusion proteins
CA2839622A1 (en) * 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof
AU2013202648B2 (en) * 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
KR101509020B1 (ko) * 2013-05-22 2015-04-14 (주)입디 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
CA3161989A1 (en) * 2014-07-23 2016-01-28 Inova Diagnostics, Inc. Compositions and methods for the diagnosis of rheumatoid arthritis
IL308589A (en) * 2014-10-27 2024-01-01 Inhibrx Inc Serpin-fused polypeptides and methods of using them
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11422719B2 (en) * 2016-09-15 2022-08-23 Pure Storage, Inc. Distributed file deletion and truncation
EP3600345A4 (en) * 2017-03-29 2021-01-06 Cornell University OXIDIZATION RESISTANT AAT GENE THERAPY
JP7291119B2 (ja) 2017-07-27 2023-06-14 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）阻害剤および使用方法
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
ES2975208T3 (es) 2017-12-01 2024-07-04 Csl Behring Llc A1AT para reducir el riesgo de aparición de la enfermedad aguda de injerto contra huésped tras el trasplante de células hematopoyéticas
JP7731288B2 (ja) * 2018-10-29 2025-08-29 スピン セラピューティクス， エルエルシー アルファ－１－アンチトリプシン欠乏症のための組成物及び方法
CA3140664A1 (en) 2019-06-24 2020-12-30 Roman Fischer Tnfr2 agonists with improved stability
US20220267412A1 (en) * 2019-08-01 2022-08-25 Serplus Technology Llc Oxidation-resistant serpins
EP4061956A4 (en) * 2019-11-21 2023-11-01 The Regents Of The University Of Michigan POLYPEPTIDE INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY AND THEIR USES
CN110964094B (zh) * 2019-12-20 2021-11-02 华中科技大学 人源白细胞蛋白酶抑制因子及其重组制备与应用
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
CA3206022A1 (en) * 2021-01-26 2022-08-04 Traian Sulea Ace2-receptor ectodomain fusion molecules and uses thereof
GB202102258D0 (en) 2021-02-17 2021-03-31 Arecor Ltd Novel composition
WO2023122120A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Compositionsand methods for wound healing
EP4526331A1 (en) 2022-05-16 2025-03-26 Sanofi AATD Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject
CN115466323B (zh) * 2022-09-13 2025-07-01 宁波博睿瀚达生物科技有限公司 一种分离分泌性白细胞蛋白酶抑制因子的方法
EP4483951A1 (en) * 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025083294A2 (en) 2024-02-29 2025-04-24 Ageronix SA Aat-fc fusion protein

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1161532A1 (en) * 1999-03-01 2001-12-12 Human Genome Sciences, Inc. Human serpin proteins
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
DE60028970T2 (de) 1999-07-02 2007-02-15 Genentech Inc., San Francisco An her2 bindende peptidverbindungen
WO2001040249A1 (en) 1999-12-01 2001-06-07 Human Genome Sciences, Inc. Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
BR0115215A (pt) * 2000-11-08 2003-12-30 Prometic Biosciences Inc Método para o tratamento de inflamações
ATE437891T1 (de) 2000-12-07 2009-08-15 Lilly Co Eli Glp-1 fusionsproteine
US7083784B2 (en) * 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU4166102A (en) * 2000-12-18 2002-07-01 Arriva Pharmaceuticals Inc Multifunctional protease inhibitors and their use in treatment of disease
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1415664A1 (en) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds
US7427595B1 (en) * 2002-12-12 2008-09-23 Cornell Research Foundation, Inc. Use of proepithelin to promote wound repair and reduce inflammation
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2004110472A2 (en) 2003-06-12 2004-12-23 Eli Lilly And Company Fusion proteins
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
CA2512933C (en) * 2003-11-13 2011-12-06 Hanmi Pharm. Ind. Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
PT1751184E (pt) 2004-05-13 2009-11-10 Lilly Co Eli Proteínas de fusão de fgf-21
BRPI0514052A (pt) 2004-08-03 2008-05-27 Transtech Pharma Inc proteìnas de fusão rage e métodos de utilização
KR20070041781A (ko) 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
US7399746B2 (en) 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
US9296816B2 (en) * 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
WO2006129849A1 (ja) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. 抗ｃｄ１４抗体融合蛋白質
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
AU2006280004A1 (en) 2005-08-12 2007-02-22 Schering Corporation MCP1 fusions
KR20200041386A (ko) * 2005-11-23 2020-04-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US8367615B2 (en) 2006-03-30 2013-02-05 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
EA017733B1 (ru) 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
WO2008138017A2 (en) 2007-05-08 2008-11-13 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
CA2687377C (en) * 2007-05-30 2013-05-14 Genexine Co., Ltd. Immunoglobulin fusion proteins
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
WO2009045508A1 (en) * 2007-10-02 2009-04-09 Research Foundation Of City University Of New York Novel protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (es) 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
NZ590358A (en) * 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP5787757B2 (ja) 2008-08-04 2015-09-30 ファイブ プライム セラピューティックス インコーポレイテッド Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
WO2010115998A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010239861B2 (en) * 2009-04-22 2013-07-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
SE533763C2 (sv) 2009-05-04 2010-12-28 Lars Hammar Upphängningsanordning
CA2767545C (en) 2009-07-08 2019-09-17 The Curators Of The University Of Missouri High oleic acid soybean with mutant fad2-1a and fad2-1b genes and method of producing the same
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
WO2012003290A2 (en) 2010-06-30 2012-01-05 University Of Maryland, Baltimore Dental composites comprising nanoparticles of amorphous calcium phosphate
WO2012087746A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
JP5926791B2 (ja) 2011-03-29 2016-05-25 ロシュ グリクアート アーゲー 抗体Ｆｃ変種
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying serpin containing fusion proteins
CA2839622A1 (en) 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
DK2726090T3 (da) * 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
MX2014015557A (es) 2012-06-21 2015-02-24 Univ Indiana Res & Tech Corp Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2630659C2 (ru) 2012-08-02 2017-09-11 Ф. Хоффманн-Ля Рош Аг СПОСОБ ПОЛУЧЕНИЯ РАСТВОРИМОГО FcR В ВИДЕ Fc-ГИБРИДА С ИНЕРТНОЙ Fc-ОБЛАСТЬЮ ИММУНОГЛОБУЛИНА И ИХ ПРИМЕНЕНИЯ
CA3138788A1 (en) 2012-12-05 2014-06-12 Sola Biosciences Llc Protein expression enhancing polypeptides
CN203917563U (zh) 2014-03-27 2014-11-05 陈广煌 一种切角模具
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

Also Published As

Publication number Publication date
AU2017279724B2 (en) 2019-03-14
JP2024138397A (ja) 2024-10-08
WO2013003641A2 (en) 2013-01-03
US11827691B2 (en) 2023-11-28
JP2022109968A (ja) 2022-07-28
RU2642310C2 (ru) 2018-01-24
SMT201900520T1 (it) 2019-11-13
KR20210032558A (ko) 2021-03-24
MX2013015323A (es) 2014-06-23
AU2019202904B2 (en) 2021-01-07
CA2839619A1 (en) 2013-01-03
RU2698655C2 (ru) 2019-08-28
UA124083C2 (uk) 2021-07-21
RU2014102583A (ru) 2015-08-10
RU2020124172A (ru) 2022-01-21
JP2018008956A (ja) 2018-01-18
PL2726092T3 (pl) 2019-11-29
AU2021202131B2 (en) 2023-01-12
KR20250012200A (ko) 2025-01-23
MX381183B (es) 2025-03-12
US20210024613A1 (en) 2021-01-28
KR102231139B1 (ko) 2021-03-24
SG10201811256QA (en) 2019-01-30
RS59368B1 (sr) 2019-11-29
HUE046156T2 (hu) 2020-02-28
RU2728861C1 (ru) 2020-07-31
IL276534A (en) 2020-09-30
US11965017B2 (en) 2024-04-23
SI2726092T1 (sl) 2019-11-29
LT2726092T (lt) 2019-10-10
KR20140054000A (ko) 2014-05-08
CY1122195T1 (el) 2020-11-25
EP2726092A4 (en) 2015-08-19
ES2746052T3 (es) 2020-03-04
US20200102371A1 (en) 2020-04-02
KR102756547B1 (ko) 2025-01-21
CN110551223A (zh) 2019-12-10
RU2727452C1 (ru) 2020-07-21
CN110066340A (zh) 2019-07-30
AU2017279724A1 (en) 2018-01-25
RU2017145308A (ru) 2019-02-18
EP3569243A1 (en) 2019-11-20
CN110066340B (zh) 2024-06-25
US10723785B2 (en) 2020-07-28
WO2013003641A3 (en) 2013-03-21
US20180179264A1 (en) 2018-06-28
KR20200027041A (ko) 2020-03-11
CA2839619C (en) 2021-11-16
AU2012275287A1 (en) 2014-01-16
US20130330769A1 (en) 2013-12-12
ME03473B (me) 2020-01-20
RU2017145308A3 (enrdf_load_stackoverflow) 2019-02-18
IL312872A (en) 2024-07-01
PT2726092T (pt) 2019-10-08
CN103917563A (zh) 2014-07-09
AU2019202904A1 (en) 2019-05-16
BR112013033799A2 (pt) 2017-02-14
KR20220003656A (ko) 2022-01-10
DK2726092T3 (da) 2019-09-30
IL230209B (en) 2020-08-31
US20210002352A1 (en) 2021-01-07
EP2726092A2 (en) 2014-05-07
EP2726092B1 (en) 2019-06-19
JP2014523900A (ja) 2014-09-18
CA3132298A1 (en) 2013-01-03
US20130011398A1 (en) 2013-01-10
AU2012275287B2 (en) 2017-10-05
US8980266B2 (en) 2015-03-17
MX356517B (es) 2018-06-01
NZ744257A (en) 2022-10-28
SG10201601621PA (en) 2016-04-28
JP2020078325A (ja) 2020-05-28
US20250011394A1 (en) 2025-01-09
NZ619023A (en) 2015-07-31
US10730929B2 (en) 2020-08-04
US9920109B2 (en) 2018-03-20
AU2021202131A1 (en) 2021-05-06
US20150147325A1 (en) 2015-05-28
HRP20191652T1 (hr) 2019-12-13
KR102084944B1 (ko) 2020-04-17
KR20230114318A (ko) 2023-08-01
JP6674604B2 (ja) 2020-04-01
IL276534B1 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
IN2013MN02441A (enrdf_load_stackoverflow)
IN2013MN02442A (enrdf_load_stackoverflow)
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
HK1200842A1 (en) Proteins with improved half-life and other properties
TN2012000518A1 (en) Serum albumin binding molecules
IN2014CN00414A (enrdf_load_stackoverflow)
BR112014018630A2 (pt) alvejamento de glicanos de sulfato de condroitina
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
EP3546481A3 (en) Anti-interleukin 22 (il-22) antibody and uses thereof
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
MX2011013455A (es) Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
MX2009002816A (es) Proteinas de fusion de albumina.
IN2012DN02981A (enrdf_load_stackoverflow)
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX361434B (es) Proteínas de fusión npp1.
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
WO2012126118A8 (en) Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
NZ724196A (en) Uti fusion proteins
WO2012122378A3 (en) Antibody-like proteins for therapeutic and diagnostic use